Approval · Notice of Compliance 21789 · 2019
VIIBRYD: Notice of Compliance 21789
Issued January 24, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21789
- Date
- January 24, 2019
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Manufacturer's Name Change to Allergan Inc. and relevant label updates to meet PLL requirements. Administrative: Merger/Buy-out
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIIBRYD | Not yet assigned | — |
Medicinal ingredients
- VILAZODONE HYDROCHLORIDE 10 MG per TAB
- VILAZODONE HYDROCHLORIDE 20 MG per TAB
- VILAZODONE HYDROCHLORIDE 40 MG per TAB